Clinical trial NCT04151186 - References

Neoplasms — A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors

Citation(s)

•   Gao C, Yao H, Liu H, Feng Y, Yang Z
  TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer. BMC Cancer. 2019 Mar 15;19(1):237. doi: 10.1186/s12885-019-5417-7.
•   Goodman GE, Hellström I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, Hellström KE
  Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol. 1990 Jun;8(6):1083-92.
•   Goodman GE, Hellstrom I, Yelton DE, Murray JL, O'Hara S, Meaker E, Zeigler L, Palazollo P, Nicaise C, Usakewicz J, et al
  Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer
•   Hellström I, Beaumier PL, Hellström KE
  Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7059-63.
•   Hellström I, Horn D, Linsley P, Brown JP, Brankovan V, Hellström KE
  Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res. 1986 Aug;46(8):3917-23.
•   Peng XC, Zeng Z, Huang YN, Deng YC, Fu GH
  Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer. Cancer Med. 2018 Jun;7(6):2592-2600. doi: 10.1002/cam4.1494. Epub 2018 Apr 17.
•   Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O'Donnell CJ, Maderna A, Cao X, Dunn R, Snyder WB, Abraham AK, Leal M, Shetty S, Barry A, Zawel L, Coyle AJ, Dvorak HF, Jaminet SC
  Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Mol Cancer Ther. 2015 Aug;14(8):1868-76. doi: 10.1158/1535-7163.MCT-15-0188. Epub 2015 Jun 18.
•   Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, Liu Y, Huang J, Lv H, Luo C, Feng KC, Yang QM, Li XL, Han W
  CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology. 2018 May 7;7(7):e1440169. doi: 10.1080/2162402X.2018.1440169. eCollection 2018.

A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell Therapy for the TM4SF1- and EpCAM-positive Recurrent/Refractory Solid Tumors

Details for clinical trial NCT04151186